Pliant Therapeutics Inc to Discuss Results from INTEGRIS-IPF Call Transcript
Good morning, everyone. Thank you for joining us for Pliant's presentation of top line data from the INTEGRIS-IPF Phase 2 clinical trial evaluating PLN-74809 in patients with IPF. The press release that we will be referencing today is available under the Investors & Media section of our corporate website. The slides accompanying this web presentation will be available in the same section of our website following the conclusion of this call.
During today's call, we will be making forward-looking statements, including those related to the therapeutic potential of PLN-74809 and our plans for the future development of PLN-74809. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our filings with the SEC, which are available at sec.gov. Pliant undertakes no obligation to update any forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |